Clinical Trial

Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis

Study acronym: EXACT-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
Trial Details
NCT Number NCT07137819
Lead Sponsor Aresus Pharma GmbH
Conditions Actinic Keratosis of Face and Scalp
Enrollment 280 participants
Start Date 2024-09-04
Primary Completion 2026-03 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-22